<DOC>
	<DOCNO>NCT01141881</DOCNO>
	<brief_summary>Purpose : evaluate effect intravitreal injection tissue plasminogen activator ( tPA ) treatment refractory diabetic macular edema ( DME ) .</brief_summary>
	<brief_title>Evaluation Role Intravitreal Tissue Plasminogen Activator Treatment Refractory Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1. type 2 diabetes 2 . Non proliferative diabetic retinopathy ( NPDR ) stage diabetic retinopathy 3. patient refractory DME CSME ( patient last MPC least 3 month improvement observe BCVA , macular thickness inOCT , clinical examination fundus photograph patient ) 4 . Absence PVD Bscan 5 . Absence PVD OCT macular area optic disk 6 . Absence PVD slit lamp biomicroscopy ( SLE ) 7. last PRP session least 3 month ago . 8 . Absence traction macula clinical examination OCT 1 . One eye patient 2 . Patients candidate intraocular surgery . 3 . Patients history glaucoma ocular hypertension 4 . Patients history vitrectomy study eye 5 . Not able refer next visit 6 . Eyes cataract make assessment macula impossible . 7 . Intraretinal hemorrhage fovea interfere OCT. 8 . BCVA â‰¤ 0.1</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Tissue Plasminogen activator ,</keyword>
	<keyword>Clinically significant macular edema ,</keyword>
	<keyword>Refractory Diabetic macular edema ,</keyword>
	<keyword>posterior vitreous detachment</keyword>
</DOC>